14 septembre 2020

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01

Marseille, France, September 10, 2020 – ImCheck Therapeutics announced today that the independent Safety Review Committee for the EVICTION Phase I/II clinical trial for its lead antibody ICT01 (NCT04243499) unanimously approved dose escalation in the solid tumor indications and the start of enrollment in the two other arms of the study: treatment with ICT01 in patients with hematologic malignancies as monotherapy and in solid tumor patients in combination with pembrolizumab. The first patients in the second cohort have now been treated. To know more